Navigation Links
Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements

p>-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such


-- the Company's ability to retain compliance with the NASDAQ's listing

qualifications; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.


Nichol Harber

Genta Investor Relations


SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Auditors for Genta Incorporated Express Going Concern Qualification
2. Genta Announces Senior Management Changes
3. Genta Announces Common Stock Offering of Approximately $3.1 Million
4. Genta Incorporated to Present at the BIO CEO & Investor Conference
5. Genta Receives Notice of Non-Compliance With NASDAQ Rule
6. Genta Receives NASDAQ Non-Compliance Notice
7. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
8. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
9. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
10. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
11. Syngenta Licenses Chromatin Gene Stacking Technology
Post Your Comments:
(Date:7/29/2014)... , July 29, 2014  Pomerantz LLP is ... Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  Such investors ... at or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On July 29, 2014, Impax Laboratories, Inc. ...
(Date:7/29/2014)... CLARA, Calif. , July 29, 2014 /PRNewswire-iReach/ ... services agreement with FORMA Therapeutics, Inc., to provide ... and proprietary fragment-based lead discovery platform for novel ... really excited about the opportunity to work with ... fields of epigenetics and protein homeostasis. FORMA Therapeutics, ...
(Date:7/29/2014)... TransVac Solutions, the trusted leader in automated ... for hospitals, will be exhibiting at booth #209 at ... & Technical Exhibition Aug. 3-6 in Chicago, Ill. ... hospitals cleaner, reducing infection risk and saving millions in ... Staff will be available at booth #209 to ...
(Date:7/29/2014)... 29, 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ... increased its investment in Green Chemistry and donated more ... last year, the Company announced Monday in its new ... the World? The report comes in ... being a responsible corporate citizen, including recognition for the ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... TUSTIN, Calif., Sept. 1 Peregrine Pharmaceuticals, Inc. (Nasdaq: ... Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 ... New York Palace Hotel in New York City. , , ... the Investors section of Peregrine,s website at . ...
... COPENHAGEN and OSLO, September ... medicines company, today announced that it,has appointed two ... Robert Burns, previously CEO of Celldex Therapeutics Inc., ... new Chief Executive,Officer. Dr Alexander Duncan, previously SVP ...
... AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: ... endocrine therapy and oncology, today announced that its Senior ... will present a corporate overview at the upcoming Rodman ... September 9, 2009 at 12:30 p.m. (eastern time) in ...
Cached Biology Technology:Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 3
(Date:7/29/2014)... If you,ve ever ordered the wrong food at a restaurant, ... may have less to do with what you want and ... After analyzing 217 menus and the selections of over 300 ... International Journal of Hospitality Management showed that when it ... most: what you see on the menu and how you ...
(Date:7/29/2014)... recover from the debilitating effects of a stroke ... knowledge of neurophysiology as well as effective therapy. ... outcomes has been the primary focus of research ... since he joined the NJIT faculty more than ... is underscored by substantial funding from sources such ...
(Date:7/29/2014)... have developed an easier method to create DNAprotein ... involved in diagnosing diseases. , DNA linked to ... partnership that can be used in diagnostic techniques, ... tag proteins with DNA can be used ... visualisation of biological material. The method also provides ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3New method provides researchers with efficient tool for tagging proteins 2
... in their response to sleep deprivation, but the biological ... Researchers have now found that a genetic difference in ... sensitive to the effects of sleep deprivation. The findings, ... the University of Surrey's Sleep Research Center, appear online ...
... upon a massive database established with funds from the ... of the National Institutes of Health (NIH), scientists have ... influenza A virus epitopes--the critical sites on the virus ... reported by researchers at the La Jolla Institute for ...
... first draft of the horse genome sequence has been ... use by biomedical and veterinary researchers around the globe, ... today. , The $15 million effort to sequence the ... of the horse (Equus caballus) was funded by the ...
Cached Biology News:Individual differences in a clock gene predict decline of performance during sleep deprivation 2New details on how the immune system recognizes influenza 2New details on how the immune system recognizes influenza 3New details on how the immune system recognizes influenza 4Horse genome assembled 2Horse genome assembled 3
... 5 ml of DETACHaBEAD 19 polyclonal ... CD19 (Pan B). B cells ... and released with DETACHaBEAD CD19 are ... suitable for applications such as culturing ...
This Malachite Green Phosphate Detection Kit...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
Biology Products: